WO2022008024A2 - Gtn (glyceryl trinitrate) solution reduced respiratory distress in covid 19 patients if given by nebulization - Google Patents

Gtn (glyceryl trinitrate) solution reduced respiratory distress in covid 19 patients if given by nebulization Download PDF

Info

Publication number
WO2022008024A2
WO2022008024A2 PCT/EG2020/000016 EG2020000016W WO2022008024A2 WO 2022008024 A2 WO2022008024 A2 WO 2022008024A2 EG 2020000016 W EG2020000016 W EG 2020000016W WO 2022008024 A2 WO2022008024 A2 WO 2022008024A2
Authority
WO
WIPO (PCT)
Prior art keywords
covid
gtn
patients
given
respiratory distress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EG2020/000016
Other languages
French (fr)
Inventor
Mohamed Kamal Mohamed AHMED
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/EG2020/000016 priority Critical patent/WO2022008024A2/en
Publication of WO2022008024A2 publication Critical patent/WO2022008024A2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Definitions

  • Gtn (Glyceryl Trinitrate) Solution Reduced Respiratory Distress In Covid 19 Patients If Given By Nebulization
  • GTN glycol trinitrate
  • 1 ⁇ 4 cm of GTN solution is placed in the evaporation chamber, of Nebulizer the amount determined according to the healthy condition of the patient, his weight, and the associated disease with addition to 3 cm Normal Saline.
  • the drug is inhaled by the Nebulizer apparatus.
  • Protocol used for treatment of Covid 19 patient is only supportive
  • Supportive treatment is aimed at reliving symptoms
  • the problems is the virus is highly adaptive reproduce so rapidly. They have planty of opportunity to mutate with each new generation potentially developing resistance to whatever drugs or vaccines we develop.
  • Nitronal aqueous solution contain glycery trinitrate. 1 mg per 1 ml
  • 1 ⁇ 4 cm of GTN solution is placed in the evaporation chamber, of Nebulizer the amount determined according to the healthy condition of the patient, his weight, and the associated disease with addition to 3 cm Normal Saline.
  • the drug is inhaled by the Nebulizer apparatus.
  • the new things is one of label use of GTN (nitroglycering) gycary trinitrate by inhalation not by infusion and use in respiratory problem not in cardiac problem as the drug known

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Description

Gtn (Glyceryl Trinitrate) Solution Reduced Respiratory Distress In Covid 19 Patients If Given By Nebulization
Technical field
Problem: ARDS is series condition in sever and critical cases of Covid 19 patient Purpose: GTN (glyceryl trinitrate) solution can reduced ARDS symptoms in Covid 19patient if Given by Nabulization.
How to use (Methods):
¼ cm of GTN solution is placed in the evaporation chamber, of Nebulizer the amount determined according to the healthy condition of the patient, his weight, and the associated disease with addition to 3 cm Normal Saline. The drug is inhaled by the Nebulizer apparatus.
(Proving the effectiveness of the drug)
First: the patient was asked if he is improved or not.
Second: Place an oxymeter to measure the oxygen saturation before and after giving the solution.
Third: take and arterial blood sample and perform blood gas analysis before and after giving the solution.
Results:
Inhalation of the GTN solution by the nebulizer target the ventilated lung regions (Alveoli) lower their vascular resistance Directing blood flow to this regions and leaving the unventilated lung region.
Thus reducing shunting and Hypoxemia.
Conclusion:
GTN Solution reduced respiratory distress in Covid 19 patients if given by Nebulization. Background Art
Protocol used for treatment of Covid 19 patient is only supportive
Supportive treatment: is aimed at reliving symptoms
Till this moment no drug or vaccine present for treatment or prophylactis from a novel corona virus disease.
However many of the symptoms can be treated and therefore treatment based on the patient’s clinical condition. Moreover supportive care for infected persons can be highly effective.
The problem in the treatment of Covid 19 patient is no specific drugs or vaccines available for treatment of Covid 19 exist till now No specific antiviral treatment for Covid 19.
However, drug previously developed to treat other viril infection are being tested to see if they might also be effective against the virus that causes Covid 19.
The problems is the virus is highly adaptive reproduce so rapidly. They have planty of opportunity to mutate with each new generation potentially developing resistance to whatever drugs or vaccines we develop.
Example of drug used in treatment of Covid 19 patients
1. Hydroxyl chloroquine and chloroquine
2. Azithromycine
3. Remdisiver.
4. Tamiflu
5. Avigan
6. Convalescent. Plasma Disclosure of invention
Nitronal aqueous solution contain glycery trinitrate. 1 mg per 1 ml
Improving the respiratory distress in Covid 19 patient decrease (1 hypoxia) in mild, moderate, severe, critical patients preventing the deterioration of the condition and reach to put the patient on artificial respiratory machine if given by nebulization How to use (Methods):
¼ cm of GTN solution is placed in the evaporation chamber, of Nebulizer the amount determined according to the healthy condition of the patient, his weight, and the associated disease with addition to 3 cm Normal Saline. The drug is inhaled by the Nebulizer apparatus.
The new things is one of label use of GTN (nitroglycering) gycary trinitrate by inhalation not by infusion and use in respiratory problem not in cardiac problem as the drug known

Claims

Claims New elements needed to protect:
1. Off - label use of gycary trinitrate (nitroglycering) who is used to treat cardiac patients mainly to treat respiratory distress syndrome (ARDS) in Covid 19 patient
2. The way (method) to use the drug nitroglycerin (glycary trinitrate) solution by the nebulizer not by infusion.
PCT/EG2020/000016 2020-07-06 2020-07-06 Gtn (glyceryl trinitrate) solution reduced respiratory distress in covid 19 patients if given by nebulization Ceased WO2022008024A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EG2020/000016 WO2022008024A2 (en) 2020-07-06 2020-07-06 Gtn (glyceryl trinitrate) solution reduced respiratory distress in covid 19 patients if given by nebulization

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EG2020/000016 WO2022008024A2 (en) 2020-07-06 2020-07-06 Gtn (glyceryl trinitrate) solution reduced respiratory distress in covid 19 patients if given by nebulization

Publications (1)

Publication Number Publication Date
WO2022008024A2 true WO2022008024A2 (en) 2022-01-13

Family

ID=79553950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2020/000016 Ceased WO2022008024A2 (en) 2020-07-06 2020-07-06 Gtn (glyceryl trinitrate) solution reduced respiratory distress in covid 19 patients if given by nebulization

Country Status (1)

Country Link
WO (1) WO2022008024A2 (en)

Similar Documents

Publication Publication Date Title
AU2022241504B2 (en) Methods of administering high concentrations of nitric oxide
Schuh et al. High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma
Idris et al. Emergency department treatment of severe asthma: metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer
JP2017503801A (en) How to use inhaled nitric oxide gas for the treatment of acute respiratory distress syndrome in children
Ikeda et al. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.
US20130239962A1 (en) Methods Of Administering High Concentrations Of Nitric Oxide
CN116348113A (en) Antiviral agents for combination therapy of COVID-19 (SARS-CoV-2)
JP2014201591A (en) Method of mitigating long- and short-term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
WO2025167739A1 (en) Use of compound in preparing drug for preventing and/or treating mountain sickness
WO2017109037A1 (en) Treatment of moderate to severe influenza
RU2742116C1 (en) Anti-coronavirus agent for covid-19 combination therapy (sars-cov-2)
JP2023535710A5 (en)
RU2784998C1 (en) A METHOD FOR THE TREATMENT OF RESPIRATORY FAILURE (HYPOXEMIA) IN PATIENTS WHO HAVE HAD AN INFECTION WITH THE SARS-CoV-2 VIRUS
Granwehr In mild to moderate COVID-19, VV116 safely reduced time to sustained clinical symptom resolution
RU2806575C1 (en) Method of treating hypercapnic respiratory failure with signs of secondary pulmonary arterial hypertension
Stojanović et al. Efficacy of intravenous immunoglobulin in the treatment of a COVID-19 patient
US20240335468A1 (en) Treatment of respiratory conditions
RU2143264C1 (en) Method of treatment of patients with tracheitis
SU1701320A1 (en) Method for stopping bronchial asthma paroxysms
RU2005489C1 (en) Method for treating acute sepsis
RU2043765C1 (en) Method for treating chronic nonspecific lung diseases
Kyriakoudi et al. Colistin Concentration in Epithelial Lining Fluid (ELF), Following High-Dose Colistimethate Sodium (CMS) Nebulization, Using Two Different Nebulizers
Bennett How Should a Child Who Presents to the Emergency Room With Wheezing Be Assessed and Treated?
Abraham Guillain-Barré Syndrome
TR202012816A2 (en) Use of anticoagulants via soft mist inhaler in symptoms caused by new type of covid-19.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20943914

Country of ref document: EP

Kind code of ref document: A2